Janssen Biotech

Last updated
Janssen Biotech, Inc.
Type Subsidiary
Industry Pharmaceuticals,
Health care
Founded1979
Defunct2011  OOjs UI icon edit-ltr-progressive.svg
Headquarters Horsham, Pennsylvania,
U.S.
Key people
Michael Yang (Immunology President)
Products golimumab IV (Simponi Aria), infliximab (Remicade), golimumab (Simponi), ustekinumab (Stelara)
Parent Johnson & Johnson
Website www.janssenbiotech.com

Janssen Biotech, Inc., formerly Centocor Biotech, Inc., is a biotechnology company that was founded in Philadelphia in 1979 with an initial goal of developing new diagnostic assays using monoclonal antibody technology.

Contents

History

In 1982, Centocor transitioned into a publicly traded company. [1] In the early 1980s, the company moved to Malvern, Pennsylvania. [1] In 1984, Centocor opened an overseas plant in Leiden, the Netherlands. [2]

In 1997, eighteen years after its foundation, Centocor achieved its first year of operating profitability. [3] [4] In 1998, Centocor sold its diagnostic division to Fujirebio, Inc. [5]

In 1999, Centocor became a wholly owned subsidiary of Johnson & Johnson. [6]

In 2004, Centocor purchased a new manufacturing plant in St. Louis, Missouri, and is currently opening a new manufacturing facility in County Cork, Ireland. The Dutch plant has been expanded substantially with a $250 million investment in additional production facilities, which were opened in 2006.[ citation needed ]

In 2007, Centocor broke new ground in advertising by releasing Innerstate, believed to be the first theatrically released documentary film both created and entirely funded by a drug company, to promote Remicade (Infliximab). [7]

In 2008, Centocor, Inc. and Ortho Biotech Inc. merged to form Centocor Ortho Biotech Inc.

In June 2010, Centocor Ortho Biotech acquired RespiVert, a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases. [8]

In June 2011, Centocor Ortho Biotech changed its name to Janssen Biotech, Inc. as part of a global effort to unite the Janssen Pharmaceutical Companies around the world under a common identity. [9]

In December 2014, the company announced it would co-develop MacroGenics cancer drug candidate (MGD011) which targets both CD19 and CD3 proteins in treating B-cell malignant tumours. This could net MacroGenics up to $700 million. [10]

In January 2015, the company announced it would utilise Ionis Pharmaceuticals' (formerly Isis Pharmaceuticals) Rna-targeting technology to discover and develop antisense drugs targeting autoimmune disorders of the gastrointestinal tract. [11]

In December 2019, XBiotech Inc. announced it would sell its novel antibody treatment (bermekimab) that neutralizes interleukin-1 alpha (IL-1⍺) to Janssen Biotech, Inc. [12] [13]

Products

In 1984, Centocor developed their first product approved by the U.S. Food and Drug Administration (FDA) — a diagnostic test used to detect the rabies virus.[ citation needed ]

In 1998, the company launched its top-selling monoclonal antibody Remicade (infliximab) for its first FDA approved indication in Crohn's disease. Subsequently, Remicade's market has expanded with approvals for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and pediatric Crohn's disease. Remicade was approved for plaque psoriasis in September 2006.

Centocor also markets ReoPro (abciximab), a biologic agent indicated as an adjunct to coronary angioplasty (PTCA).

In 2009, the U.S. FDA approved Simponi, a human monoclonal antibody for treatment for arthritis, which was co-developed with Medarex, Inc. [14]

Related Research Articles

<span class="mw-page-title-main">Johnson & Johnson</span> American multinational pharmaceutical and consumer goods corporation

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

<span class="mw-page-title-main">Infliximab</span> Pharmaceutical drug

Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease. It is given by slow injection into a vein, typically at six- to eight-week intervals.

Genentech, Inc., is an American biotechnology corporation which became a subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.

Adalimumab, sold under the brand name Humira, among others, is a monoclonal antibody used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. It is administered by injection under the skin.

Takeda Oncology is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.

<span class="mw-page-title-main">Janssen Pharmaceuticals</span> Belgian pharmaceutical company

Janssen Pharmaceuticals is a pharmaceutical company headquartered in Beerse, Belgium, and wholly-owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen.

Hubert Jacob Paul Schoemaker was a Dutch biotechnologist. He was a co-founder and the president of one of America's first biotechnology companies, Centocor, which was founded in 1979 for the commercialising of monoclonal antibodies. In 1999 he founded Neuronyx, Inc., for the manufacture of stem cells and the development of stem-cell therapies.

Cetus Corporation

Cetus Corporation was one of the first biotechnology companies. It was established in Berkeley, California, in 1971, but conducted most of its operations in nearby Emeryville. Before merging with Chiron Corporation in 1991, it developed several significant pharmaceutical drugs as well as a revolutionary DNA amplification technique.

<span class="mw-page-title-main">Regeneron Pharmaceuticals</span> American biotechnology company

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.

<span class="mw-page-title-main">Jan Vilček</span> Slovak immunologist (born 1933)

Jan T. Vilček is a biomedical scientist, educator, inventor and philanthropist. He is a professor in the department of microbiology at the New York University School of Medicine, and chairman and CEO of The Vilcek Foundation. Vilček, a native of Bratislava, Slovakia, received his M.D. degree from Comenius University Medical School, Bratislava in 1957; and his Ph.D. in Virology from the Institute of Virology, Czechoslovak Academy of Sciences, Bratislava, Czechoslovakia in 1962. In 1964, Vilček, with his wife Marica, defected from Communist Czechoslovakia during a three-day visit to Vienna. In 1965, the Vilčeks immigrated to the United States, and have since lived in New York City. Vilček devoted his scientific career to studies of soluble mediators that regulate the immune system (cytokines), including interferon and tumor necrosis factor (TNF).

Ustekinumab, sold under the brand name Stelara is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, targeting both IL-12 and IL-23.

<span class="mw-page-title-main">Golimumab</span> Pharmaceutical drug

Golimumab is a human monoclonal antibody which is used as an immunosuppressive medication and sold under the brand name Simponi. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule and hence is a TNF inhibitor. Profound reduction in C-reactive protein (CRP) levels, interleukin (IL)-6, intercellaular adhesion molecules (ICAM)-1, matrix metalloproteinase (MMP)-3, and vascular endothelial growth factor (VEGF) demonstrates golimumab as an effective modulator of inflammatory markers and bone metabolism.

Medarex was an American biopharmaceutical company based in Princeton, New Jersey, with manufacturing facilities in Bloomsbury and Annandale, New Jersey, and research facilities in Milpitas and Sunnyvale, California. In 2009, Medarex was purchased by Bristol Myers Squibb.

Innerstate is a 2007 documentary film on the "inner states" of three adults living with chronic diseases of the immune system: psoriasis, Crohn's disease, and rheumatoid arthritis. The film was produced and directed by Chris Valentino and was funded by Centocor Inc., a biomedicines company. According to the New York Times, the film is "an unusual form of soft-pedal marketing of a blockbuster drug, Remicade". Remicade (Infliximab) is a medication used to treat autoimmune diseases made by Centocor, a unit of Johnson & Johnson.

Sir Marc Feldmann,, is an Australian-educated British immunologist. He is a professor at the University of Oxford and a Senior Research Fellow at Somerville College, Oxford.

MorphoSys AG is a biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany and has a wholly owned subsidiary, MorphoSys US Inc., in Boston MA in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.

Indium (111In) biciromab was a drug targeting fibrin, a protein involved in the clotting of blood. It was the Fab' fragment of a mouse monoclonal antibody labelled with the radioisotope indium-111 for the diagnosis of thromboembolism, but was withdrawn during clinical trials.

Celltrion is a biopharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion. Celltrion's founder, Jung Jin Seo, is the richest person in South Korea.

Ionis Pharmaceuticals Biotechnology company

Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has 4 drugs in pivotal studies: tominersen for Huntington’s disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.

References

  1. 1 2 George, John (26 October 1998). "Centocor making its mark in biotech". Philadelphia Business Journal. Retrieved 2020-05-04.
  2. ↑ George, John (26 October 2011). "Johnson & Johnson '05 plant explosion: A lesson learned". Philadelphia Business Journal.
  3. ↑ "Trend For 1997 Strong Sales Continues In USA - Pharmaceutical industry". www.thepharmaletter.com. Retrieved 2020-05-04.
  4. ↑ Bishop, Todd (24 May 1999). "Centocor profit growth best among Phila. Inc". Philadelphia Business Journal.
  5. ↑ Centocor reaches agreement to sell oncology diagnostics business, 1998 press release
  6. ↑ Langreth, Robert (1999-07-22). "Johnson & Johnson to Purchase Centocor for $4.9 Billion in Stock". Wall Street Journal. ISSN   0099-9660 . Retrieved 2020-05-04.
  7. ↑ Saul, Stephanie (2007-02-21). "Drug Gets a Cameo in a Film Backed by Its Maker". The New York Times. ISSN   0362-4331.
  8. ↑ Centocor Ortho Biotech Acquires RespiVert Archived 2010-06-05 at the Wayback Machine News article from InfoGrok.
  9. ↑ George, John. "Remicade maker Centocor Ortho Biotech changing name". Philadelphia Business Journal. Retrieved 15 January 2019.
  10. ↑ "Janssen Joins MacroGenics in Up-to-$700M Cancer Collaboration". GEN - Genetic Engineering and Biotechnology News. 2014-12-22. Retrieved 2019-12-11.
  11. ↑ "Janssen, Isis Pharma Ink Up-to-$835M Antisense Agreement". GEN - Genetic Engineering and Biotechnology News. 2015-01-05. Retrieved 2019-12-11.
  12. ↑ "XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen". BioSpace. Retrieved 2020-05-04.
  13. ↑ "Janssen to Acquire Investigational Bermekimab from XBiotech". BioSpace. Retrieved 2020-05-04.
  14. ↑ Marcial, Gene (4 May 2009). "Marcial: Medarex, a Bright Spot in Biotech". businessweek.com. Retrieved 24 Sep 2014.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.